Compare BTDR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | TRVI |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | 34 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2021 | 2019 |
| Metric | BTDR | TRVI |
|---|---|---|
| Price | $5.67 | $13.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $20.92 | ★ $28.18 |
| AVG Volume (30 Days) | ★ 10.1M | 1.6M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $54.56 | N/A |
| Revenue Next Year | $70.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.03 | $9.82 |
| 52 Week High | $20.72 | $20.22 |
| Indicator | BTDR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 48.85 |
| Support Level | $5.03 | $13.00 |
| Resistance Level | $13.15 | $14.75 |
| Average True Range (ATR) | 0.73 | 0.92 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 19.28 | 39.87 |
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.